218 related articles for article (PubMed ID: 37270847)
1. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Subbiah V; Sahai V; Maglic D; Bruderek K; Touré BB; Zhao S; Valverde R; O'Hearn PJ; Moustakas DT; Schönherr H; Gerami-Moayed N; Taylor AM; Hudson BM; Houde DJ; Pal D; Foster L; Gunaydin H; Ayaz P; Sharon DA; Goyal L; Schram AM; Kamath S; Sherwin CA; Schmidt-Kittler O; Jen KY; Ricard F; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Casaletto JB
Cancer Discov; 2023 Sep; 13(9):2012-2031. PubMed ID: 37270847
[TBL] [Abstract][Full Text] [Related]
2. Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.
Schönherr H; Ayaz P; Taylor AM; Casaletto JB; Touré BB; Moustakas DT; Hudson BM; Valverde R; Zhao S; O'Hearn PJ; Foster L; Sharon DA; Garfinkle S; Giordanetto F; Lescarbeau A; Kurukulasuriya R; Gerami-Moayed N; Maglic D; Bruderek K; Naik G; Gunaydin H; Mader MM; Boezio AA; McLean TH; Chen R; Wang Y; Shaw DE; Watters J; Bergstrom DA
Proc Natl Acad Sci U S A; 2024 Feb; 121(6):e2317756121. PubMed ID: 38300868
[TBL] [Abstract][Full Text] [Related]
3. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal Secondary
Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
[TBL] [Abstract][Full Text] [Related]
5. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
Wu Q; Zhen Y; Shi L; Vu P; Greninger P; Adil R; Merritt J; Egan R; Wu MJ; Yin X; Ferrone CR; Deshpande V; Baiev I; Pinto CJ; McLoughlin DE; Walmsley CS; Stone JR; Gordan JD; Zhu AX; Juric D; Goyal L; Benes CH; Bardeesy N
Cancer Discov; 2022 May; 12(5):1378-1395. PubMed ID: 35420673
[TBL] [Abstract][Full Text] [Related]
6. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
Balasooriya ER; Wu Q; Ellis H; Zhen Y; Norden BL; Corcoran RB; Mohan A; Martin E; Franovic A; Tyhonas J; Lardy M; Grandinetti KB; Pelham R; Soroceanu L; Silveira VS; Bardeesy N
Clin Cancer Res; 2024 May; 30(10):2181-2192. PubMed ID: 38437671
[TBL] [Abstract][Full Text] [Related]
7. Futibatinib for
Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
[TBL] [Abstract][Full Text] [Related]
8. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
[TBL] [Abstract][Full Text] [Related]
9. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.
Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N
Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.
Garmezy B; Borad MJ; Bahleda R; Perez CA; Chen LT; Kato S; Oh DY; Severson P; Tam BY; Quah CS; Harding JJ
Cancer Res Commun; 2024 Apr; 4(4):1165-1173. PubMed ID: 38602417
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
[TBL] [Abstract][Full Text] [Related]
14.
Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
[TBL] [Abstract][Full Text] [Related]
15. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
16. FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures.
Sridharan V; Neyaz A; Chogule A; Baiev I; Reyes S; Barr Fritcher EG; Lennerz JK; Sukov W; Kipp B; Ting DT; Deshpande V; Goyal L
Clin Cancer Res; 2022 Dec; 28(24):5431-5439. PubMed ID: 36190545
[TBL] [Abstract][Full Text] [Related]
17. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
18. Gatekeeper Mutations and Intratumoral Heterogeneity in
Smyth EC; Babina IS; Turner NC
Cancer Discov; 2017 Mar; 7(3):248-249. PubMed ID: 28264865
[TBL] [Abstract][Full Text] [Related]
19. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
[TBL] [Abstract][Full Text] [Related]
20. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
